Explore the vast range of titles available.

Skin cancer rates are rising sharply in the United States, yet prevention and awareness, especially in underserved communities, remain limited. Compounding this, most medical schools lack a dedicated dermatology curriculum, leaving new physicians underprepared to manage common skin conditions. To address these gaps, we organized a skin screening fair at the Birmingham Free Clinic in Pittsburgh, providing underserved patients with dermatologic care and medical students with practical experience. Thirty students participated, with knowledge scores significantly improving from an average of 51.7% pre-test to 83.4% three months after the event. These findings highlight the value of incorporating community-based dermatology events into medical education to enhance dermatological training and improve access to care.

LDOM has enhanced treatment options for female AGA, yet its combined efficacy with therapies such as spironolactone, finasteride, or dutasteride remains inadequately explored. This study aims to compare the efficacy and safety of LDOM in combination with spironolactone versus LDOM with finasteride or dutasteride in women with AGA. Our analysis revealed that both combination therapies produced similar improvements in hair growth and had comparable safety profiles. Although the LDOM with finasteride/dutasteride group showed a greater average increase in hair width and density, these differences were not statistically significant. These results endorse the use of LDOM in combination with either spironolactone or finasteride/dutasteride for female AGA, and underscore the necessity for further research to validate these findings and assess long-term treatment outcomes.

Androgenetic alopecia (AGA) significantly impacts patients’ psychological well-being, and treatment options have historically been limited. However, the advent of low-dose oral minoxidil (LDOM) has revolutionized AGA management. This study compares the treatment response and safety of LDOM in patients with AGA alone versus those with AGA unmasked by telogen effluvium. Our findings indicate that LDOM is effective and safe for both groups, showing comparable efficacy and safety profiles. These results support the use of LDOM as a reliable treatment option for AGA, potentially improving patient outcomes and quality of life.

Objectives: We aim to examine the h(5) index of U.S. otolaryngology programs to help assess current academic productivity. Methods: A total of 116 otolaryngology departments with residency programs were included. Our primary outcome was the h(5) index, calculated cumulatively for faculty MDs, DOs, and PhDs within the department. Audiologists and clinical adjunct faculty were excluded. This was calculated over a 5-year period (2015–2019) using Elsevier’s database SCOPUS. Faculty affiliation within SCOPUS was confirmed by cross-referencing department websites. The h(5) indices were calculated and then correlated with other publication metrics, including total publications by department and publications in major otolaryngology journals. Results: The h(5) index was highly correlated positively with other metrics of academic productivity, including total publications and publications in top 10 otolaryngology journals. Greater variability in data was noted as the h(5) index increased. Similar trends were observed when the h(5) was compared to the number of residents accepted per year. Rankings of departments by Doximity and US News and World Report were positively correlated with h(5) though they remained weaker when compared to other correlations. Conclusions: h(5) indices are a valuable tool to objectively assess academic productivity for otolaryngology residency departments. They are a better indicator of academic productivity than national rankings.

Alopecia areata (AA) has long been considered a challenging clinical condition, with dermatologists traditionally employing corticosteroids and immunosuppressants in search of effective solutions. The introduction of Janus kinase inhibitors (JAKi), specifically the Food and Drug Administration (FDA) approval of baricitinib, marked a significant breakthrough in the treatment of AA. Clinical trials have shown promising results with baricitinib, and reports of relapse after initial success are scarce. We present a unique case of a 30-year-old male with severe patch-type AA who initially responded well to baricitinib treatment but later experienced a relapse despite continued treatment.

Keratosis pilaris atrophicans faciei (KPAF) and frontal fibrosing alopecia (FFA) present diagnostic challenges due to their similar clinical characteristics. Dermatologists often employ overlapping treatment regimens, which may hinder accurate diagnosis and treatment expectations. Genetic testing offers promise for precise diagnosis and tailored treatment strategies, yet its utility in these conditions remains underexplored. This manuscript presents a unique case study of a 36-year-old male with symptoms of both KPAF and FFA, who underwent genetic testing. Despite testing negative for this mutation, the case underscores the potential of genetic testing to enhance diagnostic accuracy and optimize treatment outcomes.

Low dose oral minoxidil (LDOM) is an efficacious and safe treatment for alopecia, however, a notable side effect is hypertrichosis. Spironolactone, known for treating hirsutism, is also used off-label for the treatment of certain forms of alopecia and may reduce LDOM-induced hypertrichosis. We performed a retrospective review of 54 patients seen at NYU Langone Health and compared hypertrichosis rates in female alopecia patients on LDOM monotherapy versus those on combination therapy with spironolactone. Among 54 patients, 37 received LDOM alone and 17 received the combination. Hypertrichosis developed in 33.3% of patients, with lower rates in the combination group (17.6% vs. 40.5% for monotherapy). Although not statistically significant, the trend suggests spironolactone may mitigate hypertrichosis. The study highlights the potential of combination therapy to address hypertrichosis and calls for larger studies to confirm these findings.

Objectives: We aim to examine the h (5) index of U.S. otolaryngology programs to help assess current academic productivity. Methods: A total of 116 otolaryngology departments with residency programs were included. Our primary outcome was the h (5) index, calculated cumulatively for faculty MDs, DOs, and PhDs within the department. Audiologists and clinical adjunct faculty were excluded. This was calculated over a 5-year period (2015–2019) using Elsevier’s database SCOPUS. Faculty affiliation within SCOPUS was confirmed by cross-referencing department websites. The h (5) indices were calculated and then correlated with other publication metrics, including total publications by department and publications in major otolaryngology journals. Results: The h (5) index was highly correlated positively with other metrics of academic productivity, including total publications and publications in top 10 otolaryngology journals. Greater variability in data was noted as the h (5) index increased. Similar trends were observed when the h (5) was compared to the number of residents accepted per year. Rankings of departments by Doximity and US News and World Report were positively correlated with h (5) though they remained weaker when compared to other correlations. Conclusions: h (5) indices are a valuable tool to objectively assess academic productivity for otolaryngology residency departments. They are a better indicator of academic productivity than national rankings.

Direct-to-consumer (DTC) telehealth platforms have enhanced healthcare accessibility and convenience, particularly for Individuals in remote areas or those with mobility limitations. These platforms offer virtual medical consultations and prescription services, improving access to treatment for conditions such as hair loss, anxiety, depression, and sexual dysfunction. However, concerns regarding limited physician oversight, lack of transparency in provider qualifications, privacy risks, and potential financial and legal vulnerabilities highlight the need for stricter regulations. Addressing these issues is crucial to ensure patient protection and trust as the use of DTC telehealth services continues to grow.